RBC Capital analyst Brian Abrahams raised the firm’s price target on Apogee Therapeutics (APGE) to $70 from $60 and keeps an Outperform rating on the shares. Following the firm’s opportunity to catch up with Apogee’s senior management on the latest updates to their clinical programs and developments in the AD – atopic dermatitis – space, RBC notes that its discussion has reaffirmed its confidence that the upcoming AD readouts should look favorable, the analyst tells investors in a research note. With timeline acceleration and the space continuing to grow, Apogee’s ‘777 and future combos can be poised to drive meaningful revenue opportunity, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Craig-Hallum bullish on Apogee Therapeutics, initiates with a Buy
- Apogee Therapeutics initiated with a Buy at Craig-Hallum
- Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment
- Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know
- Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis